Roy Maute is the CEO and co-founder of Pheast Therapeutics, a clinical-stage biotechnology company developing novel innate immune checkpoint inhibitors to revolutionize cancer treatment.
At Pheast, Roy leads development of PHST001, an anti-CD24 monoclonal antibody targeting macrophage checkpoints. The FDA has granted Fast Track Designation for advanced platinum-resistant ovarian cancer.
Before founding Pheast, Dr. Maute served as Director of Translational Research at Forty Seven Inc., leading the biomarker strategy for the breakthrough anti-CD47 program. Following Forty Seven's $4.9 billion acquisition by Gilead Sciences in 2020, he launched Pheast in 2021. He also co-founded Ab Initio Biotherapeutics, which was acquired by Ligand Pharmaceuticals in 2019.
With a PhD from Columbia, a BA from UC Berkeley, and deep translational science expertise, Roy's journey from pioneering CD47 biology to building Pheast's CD24 platform demonstrates how scientific insight can activate the immune system to eliminate cancer.
.png)